Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Return on Equity (2016 - 2025)

Cardiff Oncology's Return on Equity history spans 14 years, with the latest figure at 0.97% for Q4 2025.

  • For Q4 2025, Return on Equity fell 29.0% year-over-year to 0.97%; the TTM value through Dec 2025 reached 0.97%, down 29.0%, while the annual FY2025 figure was 0.71%, 12.0% down from the prior year.
  • Return on Equity for Q4 2025 was 0.97% at Cardiff Oncology, down from 0.94% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.16% in Q1 2021 and bottomed at 0.97% in Q4 2025.
  • The 5-year median for Return on Equity is 0.5% (2023), against an average of 0.51%.
  • The largest annual shift saw Return on Equity surged 234bps in 2021 before it crashed -32bps in 2024.
  • A 5-year view of Return on Equity shows it stood at 0.21% in 2021, then crashed by -73bps to 0.36% in 2022, then crashed by -62bps to 0.59% in 2023, then fell by -17bps to 0.69% in 2024, then plummeted by -42bps to 0.97% in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Return on Equity are 0.97% (Q4 2025), 0.94% (Q3 2025), and 0.79% (Q2 2025).